Diversity Enrichment: US FDA Guidance Suggests Sponsors May Need To Overenroll Key Groups

 
• By Sarah Karlin-Smith
  
Generate a summary of this article
Listen to this article
Beta

New draft guidance on clinical trial diversity action plans pushes for disproportionately high enrollment of traditionally underrepresented groups, while also asking companies to tailor global programs to US populations and consider diversity aspects that Congress did not outline. 

overflowing coffee cup with coffee spilled on table
While greater than proportional enrollment may be necessary, the FDA will not conduct statistical testing on population subgroups. • Source: Shutterstock

Medical device and drug sponsors may need to overenroll key patient populations under the US Food and Drug Administration’s new diversity action plan guidance, a move that could make the revamped clinical trial diversity push more challenging than anticipated.

Key Takeaways

  • Aiming high for diversity, the FDA says greater than proportional enrollment for some subpopulations may be warranted as targets in soon-to-be required diversity action plans, but says it will not do statistical testing on population subgroups.

The 2022 Food and Drug Omnibus Reform Act (FDORA) implemented a requirement for sponsors to submit “diversity action plans” for...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

SpotifyApple PodcastsWebsite

More from Diversity & Inclusion

FDA Looks To Achieve Greater Health Equity For Medical Device Access

 
• By Brian Bossetta

The US FDA has published a discussion paper as part of an effort to ensure all patients have timely access to safe and effective medical devices. The agency says the paper fits into a larger strategy of promoting health equity and is seeking public comment on the initiative.

Medtechs Are Fully Engaged In Climate Change: ‘They Have No Choice’

 
• By Ashley Yeo

The E in ESG: SUDs, reuse, disposables, refurbishing, reprocessed devices? Multiple panelists at the 2024 MedTech Forum addressed the role medtech manufacturers should have in the climate change challenge.

FDA's LDT Overhaul Should Go Back To Congress, Appropriations Report Says

 
• By Sarah Karlin-Smith and Elizabeth Orr

A fiscal 2025 report from the US House Appropriations Committee instructs the FDA to halt implementation of its overhaul of LDT regulation. Members also showed concern about overseas device manufacturing and the availability of over-the-counter diagnostics. 

Diversity Action Plans Should Be Brief And Waiver Requests Filed Early, US FDA Says

 
• By Sue Sutter and Ryan Nelson

In what could amount to a de facto enforcement mechanism, the new draft guidance also “strongly encourages” sponsors to share details about their diversity action plan and enrollment goals with the public.

More from ESG

EU’s Historic PFAS Restriction Looms Over Medical Devices Sector

 
• By Ryan Nelson

The European Chemicals Agency’s committees for Risk Assessment (RAC) and Socio-Economic Analysis (SEAC) are evaluating sector by sector the proposed REACH restriction on PFAS and more than 5,600 public comments, reaching provisional conclusions on cosmetics at their June meetings. A date has not been set to consider PFAS uses in medical devices, which are numerous, essential, and in many cases devoid of alternatives, industry says.

Diversity Action Plans Should Be Brief And Waiver Requests Filed Early, US FDA Says

 
• By Sue Sutter and Ryan Nelson

In what could amount to a de facto enforcement mechanism, the new draft guidance also “strongly encourages” sponsors to share details about their diversity action plan and enrollment goals with the public.

Diversity Enrichment: US FDA Guidance Suggests Sponsors May Need To Overenroll Key Groups

 
• By Sarah Karlin-Smith

New draft guidance on clinical trial diversity action plans pushes for disproportionately high enrollment of traditionally underrepresented groups, while also asking companies to tailor global programs to US populations and consider diversity aspects that Congress did not outline.